Morepen Lab Shares Skyrocket 19% on Getting a Rs 825 Crore Contract 

Shares of Morepen Laboratories Limited skyrocketed 19% on 23 February after the company announced a multi-year Contract Development and Manufacturing Organisation (CDMO) mandate worth around Rs 825 crore from a renowned global pharmaceutical business.

According to a press release filed with the exchanges, Morepen expects shipments under the agreement to begin over the next four to five months, with execution slated for the first quarter of the next fiscal year, subject to standard operational and regulatory processes.

The CDMO platform is intended to facilitate organised, multi-year supply programmes by providing comprehensive development-to-commercial manufacturing capabilities. The company is also considering capacity enhancement and technology expenditures to support its growing CDMO opportunity pipeline.

Chairman and Managing Director Sushil Suri said, “This mandate represents an important milestone in the evolution of Morepen’s manufacturing platform. It reflects the confidence global customers place in our quality systems, regulatory track record, and execution capabilities.”

The company identified the mandate as one of the largest single CDMO contracts in its history, indicating a shift in its worldwide manufacturing scale.

Suri added, “We view CDMO as a natural extension of our established API strengths, creating additional avenues of scale, stability, and long-term value creation while continuing to reinforce our core businesses.”

The collaboration expands Morepen’s existing active pharmaceutical ingredient (API) production infrastructure and regulatory accreditations, which include certifications from the US Food and Drug Administration (USFDA), WHO-GMP, and European authorities.

Morepen is a vertically integrated pharmaceutical and healthcare company that supplies APIs, branded generics, medical devices, and consumer wellness products to over 90 countries.

At 1:25 pm, the shares of Mropen Laboratories were trading 17.51% higher at Rs 46.10 on NSE.

Tired of guessing stocks to trade in daily?
Tradz by EquityPandit empowers you with powerful tools like daily stock scans for Intraday, Swing & Investing, Market Predictions and much more. Download the Tradz by EquityPandit app today and take control of your investments!

The post Morepen Lab Shares Skyrocket 19% on Getting a Rs 825 Crore Contract  appeared first on Equitypandit.